Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7978
Reference
Name
National Patient Safety Alert – Shortage of Methylphenidate prolonged-release capsules and tablets, Lisdexamfetamine capsures, and Guanfacine prolonged-release tablets
Categories
Scottish Government
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
HEALTH BOARDS
NATIONAL PATIENT SAFETY ALERT
ADHD
ATENTION DEFICIT HYPERACTIVITY DISORDER
SUPPLY DISRUPTION
Description
There are supply disruptions affecting various strengths of the following medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD): • Methylphenidate:* • Equasym XL® 10, 20 and 30 mg capsules • Xaggitin XL® 18 and 36 mg prolonged-release tablets • Concerta XL® 54 mg prolonged-release tablets • Xenidate XL® 27 mg prolonged-release tablets • Lisdexamfetamine: • Elvanse® 20, 30, 40, 50, 60 and 70 mg capsules • Elvanse® Adult 30, 50, and 70 mg capsules • Guanfacine: • Intuniv® 1, 2, 3 and 4 mg prolonged-release tablets The supply disruption of these products is caused by a combination of manufacturing issues and an increased global demand. Other ADHD products remain available but cannot meet excessive increases in demand. At present, the supply disruptions are expected to resolve at various dates between October and December 2023.
Contact Name
Irene Fazakerley
Contact Email
Contact Address
Contact Phone
Created
2023-09-27 00:00:00
Click to go back to homepage